Status
Conditions
Treatments
About
The main purpose of this study is to assess the efficacy of a partially hydrolyzed formula with synbiotics in halting one of the first steps of the allergic march (atopic dermatitis) in infants at risk of allergy. Other efficacy and safety parameters will be assessed as well.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Written informed consent has been obtained from at least one parent or legally acceptable representative (LAR), if applicable
Infant gestational age ≥ 37 completed weeks
Infant birth weight of ≥ 2.5 kg and ≤ 4.5 kg
Infant postnatal age ≤ 14 days (date of birth = day 0) at enrollment
Infant from singleton birth or infant from multiple births may if all birth siblings are enrolled.
At least one biological parent or sibling has (or had) a medically diagnosed history of allergy, based on response to a simple screening questionnaire
a. For the breastfed reference group only: infant is exclusively breastfed since birth with no intake of formula, and their parent(s) have the intention to continue exclusive breastfeeding until at least 4 months of age.
or b. For the randomized formula-fed groups only: infant is exclusively or predominantly formula-fed in the 24 hours prior to enrollment, with formula feeding representing at least 75% of total daily feeds. The decision to introduce formula feeding was independently made by the parents before enrollment.
Parents/LAR must be able to provide evidence of parental authority and identity.
Infant's parent(s)/LAR must understand the informed consent form and other study documents and are willing and able to fulfill the requirements of the study protocol.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
400 participants in 3 patient groups
Loading...
Central trial contact
Amelie Goyer, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal